Covid Shined Light on Biotech, and Bulls See Even Brighter 2021
- Biogen Alzheimer’s drug decision, M&A ramp among catalysts
- Bulls tout emerging drug platforms, cheap large-cap stocks
Photographer: Mark Lennihan/AP/Bloomberg
This article is for subscribers only.
This year’s meteoric rise in biotech stocks is here to stay.
That’s according to money managers who expect fresh tailwinds after the industry climbed to records as the advancement of Covid-19 vaccines and therapies drew praise from Wall Street.